Skip to main content
Erschienen in: Drugs 6/2013

01.05.2013 | Adis Drug Evaluation

Pasireotide: A Review of Its Use in Cushing’s Disease

verfasst von: Kate McKeage

Erschienen in: Drugs | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Pasireotide (Signifor®) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing’s disease. Pasireotide has a receptor binding profile that is distinct from that of other somatostatin analogues, binding with high affinity to somatostatin receptor subtype 5, which is strongly over expressed in corticotroph adenoma cells. Pasireotide is the first pituitary-directed agent to be approved for use in Cushing’s disease. In a phase III clinical trial in patients with Cushing’s disease, twice-daily pasireotide 600 or 900 μg for 6 months led to normalization of urinary free cortisol (UFC) levels in up to a quarter of all patients (primary endpoint) and significantly reduced mean UFC levels. The reduction in UFC levels is rapid (within one to two months) and sustained (up to 24 months). Most patients who do not have an early response to pasireotide do not respond at a later time point. Decreases in UFC levels achieved during pasireotide treatment are accompanied by decreases in serum and salivary cortisol levels, as well as improvements in clinical signs and symptoms, including body weight, blood pressure and health-related quality-of-life. Pasireotide has a generally similar tolerability profile to that of other somatostatin analogues, but is associated with a relatively high incidence of hyperglycaemia, requiring the addition or intensification of glucose-lowering medication in a substantial proportion of patients. Thus, pasireotide, together with on-going patient monitoring, provides a promising new option for the medical management of Cushing’s disease.
Literatur
1.
Zurück zum Zitat Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454–62.PubMedCrossRef Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454–62.PubMedCrossRef
2.
Zurück zum Zitat Feelders RA, Pulgar SJ, Kempel A, et al. The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167(3):311–26.PubMedCrossRef Feelders RA, Pulgar SJ, Kempel A, et al. The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167(3):311–26.PubMedCrossRef
3.
Zurück zum Zitat Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117–23.PubMedCrossRef Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117–23.PubMedCrossRef
4.
Zurück zum Zitat Reznik Y, Bertherat J, Borson-Chazot F, et al. Management of hyperglycaemia in Cushing’s disease: expert’s proposals on the use of pasireotide. Diabetes Metab. 2013;39(1):34–41.PubMedCrossRef Reznik Y, Bertherat J, Borson-Chazot F, et al. Management of hyperglycaemia in Cushing’s disease: expert’s proposals on the use of pasireotide. Diabetes Metab. 2013;39(1):34–41.PubMedCrossRef
5.
Zurück zum Zitat Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40(4):479–84.CrossRef Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40(4):479–84.CrossRef
6.
Zurück zum Zitat Patil CG, Prevedello DM, Lad SP, et al. Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab. 2008;93(2):358–62.PubMedCrossRef Patil CG, Prevedello DM, Lad SP, et al. Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab. 2008;93(2):358–62.PubMedCrossRef
7.
8.
Zurück zum Zitat Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152(4):645–54.PubMedCrossRef Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152(4):645–54.PubMedCrossRef
9.
Zurück zum Zitat Lacroix A, Pivonello R. Medical treatment of Cushing’s disease with pasireotide. Eur Endocrinol. 2012;8(2):99–104. Lacroix A, Pivonello R. Medical treatment of Cushing’s disease with pasireotide. Eur Endocrinol. 2012;8(2):99–104.
12.
Zurück zum Zitat Batista DL, Zhang X, Gejman R, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006;91(11):4482–8.PubMedCrossRef Batista DL, Zhang X, Gejman R, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006;91(11):4482–8.PubMedCrossRef
13.
Zurück zum Zitat Beglinger C, Hu K, Wang Y, et al. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, phase I study. Endocrine. 2012;42(2):366–74.PubMedCrossRef Beglinger C, Hu K, Wang Y, et al. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, phase I study. Endocrine. 2012;42(2):366–74.PubMedCrossRef
14.
Zurück zum Zitat Golor G, Hu K, Ruffin M, et al. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther. 2012;6:71–9.PubMedCrossRef Golor G, Hu K, Ruffin M, et al. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther. 2012;6:71–9.PubMedCrossRef
15.
Zurück zum Zitat Shenouda M, Maldonado M, Wang Y, et al. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels. Am J Ther. 2012. doi:10.1097/MJT.0b013e31824c3eb4. Shenouda M, Maldonado M, Wang Y, et al. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels. Am J Ther. 2012. doi:10.​1097/​MJT.​0b013e31824c3eb4​.
16.
Zurück zum Zitat Henry RR, Mudaliar S, Wetli-Hermosillo K, et al. Mechanism and management of hyperglycaemia associated with pasireotide: results from studies in healthy volunteers [abstract no. P260]. European Congress of Endocrinology; 30 Apr 4–May 2011; Rotterdam. Henry RR, Mudaliar S, Wetli-Hermosillo K, et al. Mechanism and management of hyperglycaemia associated with pasireotide: results from studies in healthy volunteers [abstract no. P260]. European Congress of Endocrinology; 30 Apr 4–May 2011; Rotterdam.
17.
Zurück zum Zitat Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med. 2010;362(19):1846–8.PubMedCrossRef Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med. 2010;362(19):1846–8.PubMedCrossRef
18.
Zurück zum Zitat van der Pas R, de Bruin C, Leebeek FWG, et al. The hypercoagulable state in Cushing’s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab. 2012;97(4):1303–10.PubMedCrossRef van der Pas R, de Bruin C, Leebeek FWG, et al. The hypercoagulable state in Cushing’s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab. 2012;97(4):1303–10.PubMedCrossRef
19.
Zurück zum Zitat Horsmans Y, Hu K, Ruffin M, et al. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study. J Clin Pharmacol. 2012;52(4):552–8.PubMedCrossRef Horsmans Y, Hu K, Ruffin M, et al. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study. J Clin Pharmacol. 2012;52(4):552–8.PubMedCrossRef
20.
Zurück zum Zitat Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115–22.PubMedCrossRef Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115–22.PubMedCrossRef
21.
Zurück zum Zitat Boscaro M, Zhang Y, Sen K, et al. Long-term treatment of Cushing’s disease with pasireotide (SOM230): results from a Phase II extension study [abstract no. P640]. European Congress of Endocrinology, Prague, 24–28 Apr 2010. Boscaro M, Zhang Y, Sen K, et al. Long-term treatment of Cushing’s disease with pasireotide (SOM230): results from a Phase II extension study [abstract no. P640]. European Congress of Endocrinology, Prague, 24–28 Apr 2010.
22.
Zurück zum Zitat Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366(10):914–24.PubMedCrossRef Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366(10):914–24.PubMedCrossRef
23.
Zurück zum Zitat Bertherat J, Schopohl J, Ludlam WH, et al. Long-term pasireotide use leads to significant and sustained improvements in the signs and symptoms of Cushing disease: 24-month results from a randomized phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23–26 Jun 2012. Bertherat J, Schopohl J, Ludlam WH, et al. Long-term pasireotide use leads to significant and sustained improvements in the signs and symptoms of Cushing disease: 24-month results from a randomized phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23–26 Jun 2012.
24.
Zurück zum Zitat Lacroix A, Ludlam W, Mantero F, et al. Initial response to pasireotide treatment is predictive of 12-month response: results of a large, randomized, double-blind, phase III study in patients with Cushing disease [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23–26 Jun 2012. Lacroix A, Ludlam W, Mantero F, et al. Initial response to pasireotide treatment is predictive of 12-month response: results of a large, randomized, double-blind, phase III study in patients with Cushing disease [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23–26 Jun 2012.
25.
Zurück zum Zitat Schopohl J, Bertherat J, Ludlam W, et al. Long-term pasireotide use leads to improvements in the biochemical parameters of Cushing’s disease: 24-month results from a randomized phase III study [abstract no. P1410]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5–9 May 2012. Schopohl J, Bertherat J, Ludlam W, et al. Long-term pasireotide use leads to improvements in the biochemical parameters of Cushing’s disease: 24-month results from a randomized phase III study [abstract no. P1410]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5–9 May 2012.
26.
Zurück zum Zitat Pivonello R, Petersenn S, Newell-Price J, et al. Pasireotide treatment in Cushing disease is associated with significant improvements in hypertension: 12-month results from a large phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23–26 Jun 2012. Pivonello R, Petersenn S, Newell-Price J, et al. Pasireotide treatment in Cushing disease is associated with significant improvements in hypertension: 12-month results from a large phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23–26 Jun 2012.
27.
Zurück zum Zitat Gadelha M, Badia X, Zgliczynski W, et al. Pasireotide treatment is associated with clinically meaningful improvements in health-related quality of life in Cushing disease: results from a large, randomized, double-blind, phase III trial [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23–26 Jun 2012. Gadelha M, Badia X, Zgliczynski W, et al. Pasireotide treatment is associated with clinically meaningful improvements in health-related quality of life in Cushing disease: results from a large, randomized, double-blind, phase III trial [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23–26 Jun 2012.
28.
Zurück zum Zitat Bertherat J, Ludlam WH, Pivonello R, et al. Pasireotide as a long-term treatment for patients with Cushing disease: 24-month safety results from a randomized phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23–26 Jun 2012. Bertherat J, Ludlam WH, Pivonello R, et al. Pasireotide as a long-term treatment for patients with Cushing disease: 24-month safety results from a randomized phase III study [abstract]. In: 94th Annual Meeting and Expo of the Endocrine Society, Houston, 23–26 Jun 2012.
29.
Zurück zum Zitat Fleseriu M, Petersenn S. Medical management of Cushing’s disease: what is the future? Pituitary. 2012;15(3):330–41.PubMedCrossRef Fleseriu M, Petersenn S. Medical management of Cushing’s disease: what is the future? Pituitary. 2012;15(3):330–41.PubMedCrossRef
30.
Zurück zum Zitat Trementino L, Cardinaletti M, Concettoni C, et al. Long-term efficacy of pasireotide in a patients with Cushing’s disease and diabetes: results in the short term are not always predictive of long-term response [abstract no. P108]. J Clin Endokrinol Stoffw. 2012;5(Special Issue 3). Trementino L, Cardinaletti M, Concettoni C, et al. Long-term efficacy of pasireotide in a patients with Cushing’s disease and diabetes: results in the short term are not always predictive of long-term response [abstract no. P108]. J Clin Endokrinol Stoffw. 2012;5(Special Issue 3).
31.
Zurück zum Zitat Libe R, Groussin L, Bertherat J. Pasireotide in Cushing’s disease [letter]. N Engl J Med. 2012;366(22):2134.PubMedCrossRef Libe R, Groussin L, Bertherat J. Pasireotide in Cushing’s disease [letter]. N Engl J Med. 2012;366(22):2134.PubMedCrossRef
32.
Zurück zum Zitat Ning G, Wang W, Maldonado M, et al. Long-term efficacy and safety of pasireotide in Cushing’s disease: a 36-month case report [abstract no. P353]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5–9 May 2012. Ning G, Wang W, Maldonado M, et al. Long-term efficacy and safety of pasireotide in Cushing’s disease: a 36-month case report [abstract no. P353]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5–9 May 2012.
33.
Zurück zum Zitat Feelders RA, Hofland LJ. Medical treatment of Cushing’s disease. J Clin Endocrinol Metab. 2013;98(2):425–38.PubMedCrossRef Feelders RA, Hofland LJ. Medical treatment of Cushing’s disease. J Clin Endocrinol Metab. 2013;98(2):425–38.PubMedCrossRef
34.
Zurück zum Zitat Ligueros-Saylan M, Zhang Y, Newell-Price J, et al. Evaluation of the efficacy and safety of pasireotide LAR in patients with mild-to-moderate Cushing’s disease: a randomized, double-blind, multicentre, phase III study design [abstract no. P1542.1]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5–9 May 2012. Ligueros-Saylan M, Zhang Y, Newell-Price J, et al. Evaluation of the efficacy and safety of pasireotide LAR in patients with mild-to-moderate Cushing’s disease: a randomized, double-blind, multicentre, phase III study design [abstract no. P1542.1]. In: 15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, 5–9 May 2012.
Metadaten
Titel
Pasireotide: A Review of Its Use in Cushing’s Disease
verfasst von
Kate McKeage
Publikationsdatum
01.05.2013
Verlag
Springer International Publishing AG
Erschienen in
Drugs / Ausgabe 6/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0052-0

Weitere Artikel der Ausgabe 6/2013

Drugs 6/2013 Zur Ausgabe